Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.67 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365767 | 0.90 | MME (0.55) | FPR2ACEMME | |
| SCHEMBL18439036 | 0.85 | FPR2 (0.77) | FPR2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL18439034 | 0.85 | FPR2 (0.77) | FPR2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6380805 | 0.81 | FPR2 (1.00) | FPR2 | |
| SCHEMBL6376031 | 0.81 | FPR2 (1.00) | FPR2 | |
| SCHEMBL6376040 | 0.81 | FPR2 (1.00) | FPR2 | |
| SCHEMBL19895755 | 0.78 | FPR2 (0.60) | FPR2MMP2MMP1MMP3MMP7 | |
| SCHEMBL18236105 | 0.78 | FPR2 (0.60) | FPR2MMP2MMP1MMP3MMP7 | |
| SCHEMBL21777173 | 0.78 | MME (0.61) | FPR2ACEMME | |
| SCHEMBL11065217 | 0.77 | ACE (0.60) | FPR2MMP2MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |